Clinical Trial

A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 16, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
The main purpose of this study is to evaluate how much lepodisiran gets into the blood stream and how long it takes the body to get rid of it when given as a subcutaneous (SC) injection under the skin to participants with mild, moderate, or severe liver function impairment compared to participants with normal liver function. The study will also evaluate how well lepodisiran is tolerated and what side effects may occur in these participants. The study will last up to approximately 9 weeks, excluding screening.
Protocol Amendment History 5 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-17
notable Primary completion moved earlier: 2026-08 -> 2026-07 2026-06-17
minor Completion moved earlier: 2026-08 -> 2026-07 2026-06-17
notable Primary completion pushed: 2026-06 -> 2026-08 2026-05-20
minor Completion pushed: 2026-06 -> 2026-08 2026-05-20
Trial Details
NCT Number NCT06916078
Lead Sponsor Eli Lilly and Company
Conditions Liver Dysfunction, Healthy
Enrollment 33 participants
Start Date 2025-04-23
Primary Completion 2026-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2026-06-16